Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment: Data from randomized clinical trials

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 1 SUPPL, 2007, Pages

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ATLIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 35748983222     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Tutuncu Z, Kavanaugh A. Biologics in the treatment of rheumatoid arthritis. In: Firestein GS, Panayi GS, Wollheim FA (eds). Rheumatoid Arthritis: The New Frontiers in Pathogenesis and Treatment. (2nd ed). Oxford: Oxford University Press, 2006, pp. 387-400.
2. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nature Clin Pract Rheumatol. 2006;2:619-26.
3. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S4-10.
4. Cronstein BN. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S11-5.
5. Strand V, Yazici Y. Tolerability profile of IL-6 inhibition and its clinical implications. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S21-4
6. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibody. Springer Seminar Immunopathol. 1998;20:247-59.
7. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxcity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis. J Rheumatol. 2003;30:1426-35.
8. Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46:3143-50.
9. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-9.
10. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(Suppl II): OP0227.
11. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-29.
12. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded controlled trial of tocilizumab. Ann Rheum Dis. 2006 May 7;[E pub ahead of print].
13. Smolen J, Beaulieu, Rubbert-Roth A, Alecock E, Alten R, Woodworth T. Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(Suppl II):OP0117.
14. Alten R, Ramos-Remus C, Rovensky J, Lucero M, Woodworth T, Smolen J. Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly improves quality of life in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl II):SAT0001.
15. Kavanaugh A, Cohen S, Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 2004;31:1881-4.
16. Koenders M, Lubberts E, van de Loo FA, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol. 2006;176:6262-9.